^
Association details:
| Biomarker: | IGF2 elevation |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | ganitumab (AMG 479) (IGF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor
Excerpt:
Median OS of ganitumab versus placebo in patients with higher levels of IGF-1, IGF-2, and IGFBP-3 was 16 versus 6.8 months (HR, 0.25; 95% CI: 0.09-0.67), 16 versus 5.9 months (HR, 0.24; 95% CI: 0.09-0.68), and 16 versus 6.8 months (HR, 0.28; 95% CI: 0.11-0.73), and in patients with lower IGFBP-2 levels was 12.7 versus 6.6 months (HR, 0.19; 95% CI: 0.07-0.55).
DOI:
10.1158/1078-0432.CCR-12-1840
